Eli Lilly and Co said on Friday it will acquire Versanis, a privately held biotech company developing a novel obesity drug, for potentially up to $1.93 billion, as it seeks to expand its presence in the lucrative weight-loss market. The deal gives Eli Lilly access to Versanis’ lead candidate, VS-01, which is being tested in…